- Home
- NCMI vs MREO Comparison
NCMI vs MREO Comparison
Compare NCMI & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCMI
- MREO
- Stock Information
- Founded
- NCMI 2005
- MREO 2015
- Country
- NCMI United States
- MREO United Kingdom
- Employees
- NCMI N/A
- MREO N/A
- Industry
- NCMI Advertising
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- NCMI Consumer Discretionary
- MREO Health Care
- Exchange
- NCMI Nasdaq
- MREO Nasdaq
- Market Cap
- NCMI 477.2M
- MREO 424.5M
- IPO Year
- NCMI 2007
- MREO N/A
- Fundamental
- Price
- NCMI $5.33
- MREO $2.22
- Analyst Decision
- NCMI Strong Buy
- MREO Strong Buy
- Analyst Count
- NCMI 5
- MREO 7
- Target Price
- NCMI $7.60
- MREO $7.71
- AVG Volume (30 Days)
- NCMI 839.2K
- MREO 943.2K
- Earning Date
- NCMI 05-06-2025
- MREO 05-13-2025
- Dividend Yield
- NCMI 1.10%
- MREO N/A
- EPS Growth
- NCMI N/A
- MREO N/A
- EPS
- NCMI N/A
- MREO N/A
- Revenue
- NCMI $238,300,000.00
- MREO N/A
- Revenue This Year
- NCMI $10.80
- MREO N/A
- Revenue Next Year
- NCMI $12.25
- MREO $54.91
- P/E Ratio
- NCMI N/A
- MREO N/A
- Revenue Growth
- NCMI 42.10
- MREO N/A
- 52 Week Low
- NCMI $4.12
- MREO $1.58
- 52 Week High
- NCMI $7.60
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- NCMI 52.41
- MREO 40.94
- Support Level
- NCMI $4.86
- MREO $2.12
- Resistance Level
- NCMI $5.50
- MREO $2.27
- Average True Range (ATR)
- NCMI 0.21
- MREO 0.13
- MACD
- NCMI 0.06
- MREO -0.02
- Stochastic Oscillator
- NCMI 84.89
- MREO 9.09
About NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).